Loading...
Market
Will ARC-EX Stimulator sales meet, exceed, or fall short of targets one year post-launch?
4
Resolution / Starting Odds
Exceeds target • 33%
Meets target • 33%
Falls short of target • 33%
Annual financial reports from Onward Medical or major financial news
Story
Onward Medical's ARC-EX Stimulator Shows Promising Results in Clinical Trial
May 20, 2024, 03:32 PM
A new non-invasive spinal cord stimulator developed by Onward Medical has shown promising results in aiding the recovery of people with spinal injuries. The device, known as ARC-EX, uses a 10 kilohertz current to numb the skin and provide stronger electrical stimulation. In a clinical trial, the stimulator improved hand and arm function in 72% of participants, including 43 individuals with tetraplegia. Approximately 18,000 people suffer from spinal cord injuries each year, and this extraordinary device could significantly enhance their rehabilitation process when paired with rehab. The results of the trial were published in Nature Medicine.
View original story
Similar markets
Exceeds market expectations • 33%
Meets market expectations • 34%
Falls below market expectations • 33%
Exceeds market expectations • 33%
Meets market expectations • 34%
Falls below market expectations • 33%
Significant improvement • 33%
Moderate improvement • 34%
No improvement or worsening • 33%
$0-100 million • 25%
$101-500 million • 25%
$501 million - $1 billion • 25%
Over $1 billion • 25%
Achieve more than 15% market share • 25%
Achieve 10-15% market share • 25%
Achieve 5-10% market share • 25%
Achieve less than 5% market share • 25%
Less than 10% increase • 25%
10% to 20% increase • 25%
20% to 30% increase • 25%
More than 30% increase • 25%
Profitable • 25%
Break-even • 25%
Minor losses • 25%
Significant losses • 25%
Less than $1 billion • 33%
$1-2 billion • 33%
More than $2 billion • 33%
Exceeds expectations • 33%
Meets expectations • 33%
Below expectations • 33%